GO:0032687 negative regulation of interferon-alpha production: Immune Homeostasis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032687 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-alpha production.
• Tight negative regulation of interferon-alpha is essential to prevent chronic type I interferonopathies such as Aicardi-Goutieres syndrome.
• Key negative regulators include SESN1, which restrains STING1-dependent signaling, and YTHDF2, which modulates IRF3 activity.
• Dysregulated interferon-alpha suppression contributes to autoinflammation, viral susceptibility, and tumor immune evasion.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of this regulatory process.
• Functional genomics screens combined with transcriptomics and proteomics can identify novel suppressors of interferon-alpha production.
Description
Negative regulation of interferon-alpha production (GO:0032687) is a biological process that stops, prevents, or reduces the frequency, rate, or extent of interferon-alpha production. Interferon-alpha is a type I interferon critical for antiviral defense, but its excessive or prolonged production drives autoinflammatory and autoimmune pathology. Therefore, understanding the molecular brakes that constrain interferon-alpha synthesis is central to immunology and therapeutic development. This article integrates authoritative QuickGO annotation with verified PubMed literature to summarize the mechanisms, key genes, disease links, and research methods relevant to GO:0032687.
negative regulation of interferon-alpha production At A Glance
| GO ID | GO:0032687 |
|---|---|
| GO term | negative regulation of interferon-alpha production |
| Ontology | biological_process |
| Synonym | inhibition of interferon-alpha production; downregulation of interferon-alpha production; negative regulation of interferon-alpha biosynthetic process; negative regulation of interferon-alpha secretion |
| Major function | Suppression of interferon-alpha synthesis and release to maintain immune homeostasis |
| Related process | Negative regulation of type I IFN signaling |
| Key regulators | SESN1, YTHDF2, IRF3, STING1 |
| Disease relevance | Aicardi-Goutieres syndrome, autoinflammation, viral infection, cancer |
What Is GO:0032687?
GO:0032687 refers to any process that negatively regulates the production of interferon-alpha, including inhibition of its biosynthesis or secretion. It encompasses molecular events that dampen signaling pathways leading to interferon-alpha gene transcription, mRNA stability, or protein release.
Why Is negative regulation of interferon-alpha production Important in Cell Biology?
Precise negative regulation of interferon-alpha production prevents harmful chronic type I interferon responses while preserving antiviral immunity. Defects in this process cause interferonopathies such as Aicardi-Goutieres syndrome, and its manipulation is relevant to viral pathogenesis and cancer immunotherapy.
• Prevents autoinflammatory damage from sustained type I interferon signaling.
• Controls antiviral defense to avoid immunopathology.
• Modulates tumor immune microenvironment and response to checkpoint blockade.
• Impacts adipogenesis and metabolic regulation via JAK/STAT1 signaling.
• Influences megakaryocytopoiesis and hematopoiesis.
• Provides targets for therapeutic intervention in interferonopathies.
• Guides development of CRISPR models for causal gene discovery.
• Helps interpret negative feedback loops in innate immunity.
What Happens During negative regulation of interferon-alpha production?
Initiation of negative feedback
In simple terms: After interferon-alpha is made, the cell turns on brakes to stop making more.
Negative regulation begins when sensors of type I interferon signaling activate feedback inhibitors. For example, SESN1 negatively regulates STING1 to maintain innate immune homeostasis, thereby limiting downstream interferon-alpha production. Similarly, negative regulation of cytoplasmic RNA-mediated antiviral signaling restrains interferon induction.
Suppression of IRF3 activity
In simple terms: A key transcription factor for interferon-alpha is switched off.
IRF3 is a central transcription factor driving interferon-alpha expression. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity, illustrating how viral and host factors converge to suppress interferon-alpha production. This step reduces transcription of interferon-alpha genes.
Modulation of STING1 signaling
In simple terms: The STING1 pathway that triggers interferon is dampened.
STING1 is a major activator of type I interferon responses. SESN1 negatively regulates STING1, preventing excessive interferon-alpha production and maintaining immune balance. This checkpoint is critical to avoid autoinflammation.
Regulation of JAK/STAT1 signaling
In simple terms: The signaling cascade downstream of interferon is tuned down.
Interferon-alpha inhibits adipogenesis via regulation of JAK/STAT1 signaling, demonstrating that negative regulation of interferon-alpha production intersects with metabolic and differentiation pathways. Negative regulation of type I IFN signaling broadly encompasses these feedback mechanisms.
Impact on hematopoiesis
In simple terms: Interferon-alpha suppression affects blood cell formation.
Regulation of megakaryocytopoiesis involves interferon-related pathways, and negative regulation of interferon-alpha production may influence platelet production and hematopoietic homeostasis.
Key Genes Involved in GO:0032687 negative regulation of interferon-alpha production
The following genes and proteins are experimentally implicated in negative regulation of interferon-alpha production or related type I interferon control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SESN1 | Negatively regulates STING1 to limit interferon-alpha production | CRISPR KO to study innate immune homeostasis |
| YTHDF2 | Modulates IRF3 activity; degraded by viral VP1 | Autophagy and m6A reader in antiviral immunity |
| IRF3 | Transcription factor for interferon-alpha; target of negative regulation | Point mutation to dissect phosphorylation sites |
| STING1 | Activator of type I IFN; inhibited by SESN1 | Knockout to assess interferon-alpha suppression |
| TREX1 | Mutations cause Aicardi-Goutieres syndrome with interferon signature | Patient-derived models for interferonopathy |
| RNASEH2A | Mutations linked to Aicardi-Goutieres syndrome | Knock-in of patient mutations |
| RNASEH2B | Mutations linked to Aicardi-Goutieres syndrome | CRISPR correction in iPSCs |
| RNASEH2C | Mutations linked to Aicardi-Goutieres syndrome | KO to study interferon-alpha regulation |
| SAMHD1 | Mutations cause Aicardi-Goutieres syndrome | Overexpression to test suppression |
| ADAR | Mutations cause Aicardi-Goutieres syndrome | Editing enzyme in interferon control |
| JAK1 | Mediates interferon-alpha signaling | KO to block feedback |
| STAT1 | Transcription factor downstream of IFN-alpha | Point mutation to study signaling |
| PD-L1 | Immune checkpoint linked to interferon responses in glioblastoma | Overexpression in tumor models |
| PD-1 | Checkpoint receptor in glioblastoma | KO in T cells for immunotherapy |
| IFNA1 | Interferon-alpha subtype; product of the regulated process | Reporter knock-in for production assays |
| IFNA2 | Interferon-alpha subtype | Overexpression to study negative feedback |
| MAVS | Adaptor in RNA sensing pathways | KO to assess interferon induction |
How Is negative regulation of interferon-alpha production Regulated?
Negative regulation of interferon-alpha production is controlled by feedback loops involving SESN1-STING1 and YTHDF2-IRF3 axes. Negative regulation of type I IFN signaling provides a broader framework for these checkpoints. Cytoplasmic RNA-mediated antiviral signaling is also subject to negative regulation, preventing excessive interferon output.
negative regulation of interferon-alpha production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TREX1 | Aicardi-Goutieres syndrome | Knockout iPSCs and interferon reporter |
| RNASEH2B | Aicardi-Goutieres syndrome | Point mutation knock-in |
| SAMHD1 | Aicardi-Goutieres syndrome | Overexpression and KO |
| YTHDF2 | Viral immune evasion | CRISPR KO in antiviral assays |
| PD-L1 | Glioblastoma immune evasion | Tumor overexpression models |
Aicardi-Goutieres syndrome and interferonopathies
Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR cause Aicardi-Goutieres syndrome, characterized by elevated interferon-related biomarkers. Defective negative regulation of interferon-alpha production contributes to this chronic type I interferonopathy.
Viral infection and immune evasion
Viruses such as foot-and-mouth disease virus exploit host machinery to degrade YTHDF2 and modulate IRF3, thereby suppressing interferon-alpha production for replication. This highlights how pathogens hijack negative regulatory pathways.
Cancer and immunotherapy
The PD-L1/PD-1 axis in glioblastoma multiforme intersects with interferon signaling, and negative regulation of interferon-alpha production may influence tumor immune evasion and checkpoint blockade responses.
Metabolic and hematopoietic disorders
Interferon-alpha inhibits adipogenesis via JAK/STAT1 signaling, linking negative regulation of interferon-alpha production to metabolic homeostasis. Interferon pathways also impact megakaryocytopoiesis and platelet production.
From negative regulation of interferon-alpha production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SESN1 suppress interferon-alpha production via STING1? | SESN1 knockout and STING1 double knockout |
| How does YTHDF2 degradation affect IRF3 activity? | YTHDF2 knockout with viral infection |
| Do AGS mutations impair negative regulation? | Patient mutation knock-in in iPSCs |
| Can JAK/STAT1 modulation alter adipogenesis? | STAT1 point mutation |
| What is the role of PD-L1 in interferon suppression? | PD-L1 overexpression in glioblastoma cells |
| Which RNA sensors are negatively regulated? | MAVS knockout reporter assays |
How to Study the negative regulation of interferon-alpha production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter | Interferon-alpha promoter activity | Screening negative regulators |
| CRISPR knockout screen | Gene requirement for interferon suppression | Discovery of novel regulators |
| RNA-seq | Interferon-stimulated gene expression | Interferonopathy profiling |
| Proteomics | Protein interactions and degradation | YTHDF2-IRF3 axis |
| Immunoblotting | Protein levels of STING1, IRF3 | Validation of KO/overexpression |
| ELISA | Secreted interferon-alpha protein | Quantifying production |
| Flow cytometry | Immune cell activation markers | PD-L1/PD-1 studies |
Transcriptional reporters for interferon-alpha
Reporter cell lines with interferon-alpha promoter-driven luciferase enable quantitative assessment of negative regulation.
CRISPR screens for regulators
Genome-wide CRISPR knockout screens can identify novel suppressors of interferon-alpha production, as demonstrated for STING1 and IRF3 pathways.
Proteomics and interactomics
Mass spectrometry can map interactions of SESN1, YTHDF2, and IRF3 to define negative regulatory complexes.
Patient-derived models
iPSCs from Aicardi-Goutieres syndrome patients with TREX1 or RNASEH2 mutations provide physiologically relevant systems to study interferon-alpha dysregulation.
How CRISPR Can Be Used to Study GO:0032687 negative regulation of interferon-alpha production
Knockout
CRISPR knockout of SESN1 or YTHDF2 can reveal their role in restraining interferon-alpha production. Knockout of STING1 or MAVS helps define pathway dependency.
Point Mutation
Point mutations in IRF3 phosphorylation sites or STAT1 can dissect signaling events that negatively regulate interferon-alpha.
Knock-in
Knock-in of Aicardi-Goutieres syndrome patient mutations in TREX1 or RNASEH2B enables study of defective negative regulation.
Overexpression
Overexpression of SAMHD1 or PD-L1 can test their capacity to suppress interferon-alpha production in relevant cell models.
How EDITGENE Supports negative regulation of interferon-alpha production Research
Researchers studying negative regulation of interferon-alpha production-related genes often need to determine whether a candidate gene is causally involved in suppressing interferon-alpha, and CRISPR-based models provide the most direct approach.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interferon-alpha production research.
Frequently Asked Questions About negative regulation of interferon-alpha production
What is negative regulation of interferon-alpha production?
It is the biological process GO:0032687 that stops, prevents, or reduces interferon-alpha production.
What genes are involved in negative regulation of interferon-alpha production?
Key genes include SESN1, YTHDF2, IRF3, STING1, and TREX1.
How does SESN1 regulate interferon-alpha?
SESN1 negatively regulates STING1 to maintain innate immune homeostasis and limit interferon-alpha production.
What diseases are linked to defective interferon-alpha suppression?
Aicardi-Goutieres syndrome and other interferonopathies are linked to mutations in TREX1, RNASEH2A/B/C, SAMHD1, and ADAR.
How do viruses evade interferon-alpha production?
Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity and suppress interferon-alpha.
What is the role of JAK/STAT1 in interferon-alpha regulation?
Interferon-alpha inhibits adipogenesis via JAK/STAT1 signaling, linking negative regulation to metabolic pathways.
Can CRISPR be used to study negative regulation of interferon-alpha production?
Yes, knockout, point mutation, knock-in, and overexpression models enable causal dissection of this process.
What methods measure interferon-alpha production?
Reporter assays, ELISA, RNA-seq, and proteomics are commonly used.
Is negative regulation of interferon-alpha production relevant to cancer?
Yes, the PD-L1/PD-1 axis in glioblastoma intersects with interferon signaling and immune evasion.
What is the GO ID for negative regulation of interferon-alpha production?
The GO ID is GO:0032687.
Conclusion
GO:0032687 negative regulation of interferon-alpha production is a critical biological process that maintains immune homeostasis by restraining type I interferon output. Dysregulation of this process underlies interferonopathies, viral immune evasion, and cancer immune evasion. CRISPR-based models and functional genomics provide powerful tools to dissect its mechanisms and identify therapeutic targets.
References
- 1. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 2. Xu L et al.. 2025. SESN1 negatively regulates STING1 to maintain innate immune homeostasis.. Autophagy 21(6):1245-1262 PMID: 39945079
- 3. Rice GI et al.. 2013. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.. Lancet Neurol 12(12):1159-69 PMID: 24183309
- 4. Arimoto KI et al.. 2018. Negative regulation of type I IFN signaling.. J Leukoc Biol PMID: 29357192
- 5. Lee K et al.. 2016. Interferon-alpha inhibits adipogenesis via regulation of JAK/STAT1 signaling.. Biochim Biophys Acta 1860(11 Pt A):2416-2427 PMID: 27424923
- 6. Caen JP et al.. 1999. Regulation of megakaryocytopoiesis.. Haemostasis 29(1):27-40 PMID: 10494032
- 7. Komuro A et al.. 2008. Negative regulation of cytoplasmic RNA-mediated antiviral signaling.. Cytokine 43(3):350-8 PMID: 18703349
- 8. Litak J et al.. 2019. PD-L1/PD-1 Axis in Glioblastoma Multiforme.. Int J Mol Sci 20(21) PMID: 31661771
